Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ADMA
vs
S&P 500
ADMA
S&P 500
Over the past 12 months, ADMA has underperformed S&P 500, delivering a return of -28% compared to S&P 500's +12% growth.
Stocks Performance
ADMA vs S&P 500
Performance Gap
ADMA vs S&P 500
Performance By Year
ADMA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ADMA Biologics Inc
Glance View
ADMA Biologics makes plasma-derived medicines, especially immune globulin therapies used to help patients with weakened immune systems fight infections. It also runs plasma collection centers, which supply the human plasma used to make those drugs. The company sells its products mainly to hospitals, specialty pharmacies, and other healthcare providers that treat patients with serious immune disorders. ADMA makes money by manufacturing and selling its approved biologic products and by collecting plasma, which is the key raw material for those medicines. This is a regulated business because plasma drugs must meet strict safety and quality standards. That makes the company less like a typical drug marketer and more like a specialized manufacturer with control over part of its own supply chain. What sets ADMA apart is its focus on a narrow area of the plasma market and its ownership of both plasma collection and drug manufacturing. That vertical setup can help it secure raw material and support products that serve specific medical needs, rather than chasing a broad range of drugs. For investors, it is best understood as a niche supplier of lifesaving plasma-based therapies with a built-in source of the material needed to make them.
